The EQ-5D-5L health status questionnaire in COPD: Validity, responsiveness and minimum important difference

Thorax

Volumn 71, Issue 6, 2016, Pages 493-500

  Nolan, Claire M ^a   Longworth, Louise ^b   Lord, Joanne ^c   Canavan, Jane L ^a   Jones, Sarah E ^a   Kon, Samantha S C ^a,d   Man, William D C ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d Hillingdon Hospital NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EQ 5D 5L HEALTH STATUS QUESTIONNAIRE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; VALIDITY; VISUAL ANALOG SCALE; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PAIN MEASUREMENT; PSYCHOLOGY; PSYCHOMETRY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

ACTIVITIES OF DAILY LIVING; AGED; FEMALE; HEALTH STATUS; HUMANS; MALE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PAIN MEASUREMENT; PSYCHOMETRICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84968624631     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207782     Document Type: Article

References (39)

1. EuroQol G. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
2. NICE. Guide to the methods of technology appraisal 2013. London: NICE, 4 Apr 2013. https://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-themethods-of-technology-appraisal-2013-pdf
3. Canavan JL, Kaliaraju D, Nolan CM, et al. Does pulmonary rehabilitation reduce peripheral blood pressure in patients with chronic obstructive pulmonary disease? Chron Respir Dis 2015;2:256-63.
4. Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015;70:213-18.
5. Stahl E, Jansson SA, Jonsson AC, et al. Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD. Health Qual Life Outcomes 2003;1:18.
6. Ringbaek T, Brondum E, Martinez G, et al. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008;102:1563-7.
7. Gillespie P, O'Shea E, Casey D, et al. The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial. BMJ Open 2013;3: e003479.
8. Cross J, Elender F, Barton G, et al. A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX). Health Technol Assess 2010;14:1-147, iii-iv.
9. Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010;35:532-9.
10. Pickard AS, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health Qual Life Outcomes 2011;9:26.
11. Agborsangaya CB, Lahtinen M, Cooke T, et al. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes 2014;12:74.
12. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.
13. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15.
14. Devlin N, van Hout B. OHE lunchtime seminar. An EQ-5D-5L value set for England. 2014; http://www.slideshare.net/OHENews/ohe-seminar-5-l-value-set-oct2014
15. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
16. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014;2:195-203.
17. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med 1991;85(Suppl B):25-31; discussion 3-7.
18. Williams JE, Singh SJ, Sewell L, et al. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001;56:954-9.
19. Kon SS, Dilaver D, Mittal M, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax 2014;69:793-8.
20. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
21. Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257-66.
22. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374:704-11.
23. Kon SS, Patel MS, Canavan JL, et al. Reliability and validity of 4-metre gait speed in COPD. Eur Respir J 2013;42:333-40.
24. Jones SE, Kon SS, Canavan JL, et al. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax 2013;68:1015-20.
25. Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992;47:1019-24.
26. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7.
27. Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013;346:f167.
28. Grocott R, Metcalfe S, Alexander P, et al. Assessing the value for money of pharmaceuticals in New Zealand - PHARMAC's approach to cost-utility analysis. N Z Med J 2013;126:60-73.
29. Guidelines for the economic evaluation of health technologies: Canada (3rd Edition). Ottawa: Canadian Agency for Drugs and Technologies in Health. 2006. http://www.inahta.org/wp-content/themes/inahta/img/AboutHTA-Guidelines-for- the-Economic-Evaluation-of-Health-Technologies.pdf
30. Lin FJ, Pickard AS, Krishnan JA, et al. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. BMC Med Res Methodol 2014;14:78.
31. Pickard AS, Wilke C, Jung E, et al. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med 2008;102: 519-36.
32. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006;27:822-32.
33. Petrillo J, van Nooten F, Jones P, et al. Utility estimation in chronic obstructive pulmonary disease: a preference for change? Pharmacoeconomics 2011;29: 917-32.
34. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999;8:45-54.
35. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14: 1523-32.
36. Zanini A, Aiello M, Adamo D, et al. Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respir Care 2015;60:88-95.
37. Pattanaphesaj J, Thavorncharoensap M. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health Qual Life Outcomes 2015;13:14.
38. Jia YX, Cui FQ, Li L, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res 2014;23:2355-63.
39. Kim TH, Jo MW, Lee SI, et al. Psychometric properties of the EQ-5D-5L in the general population of South Korea. Qual Life Res 2013;22:2245-53.